|Bid||6.00 x 800|
|Ask||6.65 x 4000|
|Day's Range||6.10 - 6.30|
|52 Week Range||2.08 - 7.98|
|Beta (3Y Monthly)||-0.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
While I still attempted to build a cushion on Monday with a couple of bigger positions in Avenue Therapeutics Inc. (NASDAQ: ATXI) and Genocea Biosciences Inc. (NASDAQ: GNCA), I’ve gotten the sense that momentum is fading and I don’t want to fall back into a pattern of chasing momentum until I get walloped with a big red trade.
Avenue Therapeutics (NASDAQ: ATXI)'s second Phase 3 trial of IV tramadol for the treatment of postoperative pain following abdominoplasty is a success. The study also includes a standard-of-care IV opioid as an active comparator: IV morphine 4 mg. In this study, IV tramadol also demonstrated similar efficacy and safety to that of IV morphine. “The strong safety and efficacy results from this second Phase 3 trial are consistent with those from the first Phase 3 trial in bunionectomy surgery and demonstrated the utility of IV tramadol in post-surgical pain management regardless of the surgery type,” said CEO Lucy Lu in a press release.
Avenue Therapeutics (ATXI) will hold its special meeting of shareholders on February 6, 2019 to consider the stock purchase and merger agreement proposed by InvaGen Pharmaceuticals. On November 13, 2018, Avenue announced an acquisition with InvaGen Pharmaceuticals which will initially provide $35 million in capital for a one-third stake in the company. Following FDA approval and the desired label, InvaGen will complete its acquisition of the company for an estimated $13.92 per share plus contingent rights to payments related to revenue and profit levels.
By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) released third quarter 2018 financial results and submitted their Form 10-Q to the SEC on November ...
Avenue Therapeutics (ATXI) announced an acquisition agreement with InvaGen Pharmaceuticals to acquire a 33.3% stake in the company for $35 million to be followed by a second stage closing in 2021 which will acquire the remaining shares for up to $180 million, subject to FDA approval and other specific terms. 5.8 million new shares will be issued at $6 per share, providing sufficient capital to advance IV tramadol to the post-approval stage. Furthermore, if the FDA grants approval and certain milestones are met, shareholders will receive payment of an estimated $13.92 per share and be eligible for contingent post-transaction consideration based on sales and profit metrics.
By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) provided their press release and their form 10-K including second quarter 2018 financial results ...